by Truveta staff | Mar 7, 2025 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
by Truveta staff | Jan 31, 2025 | Research
Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they were less likely to discontinue the GLP-1 RA medications. Among patients with T2D, higher...
by Truveta staff | Oct 30, 2024 | Research
Truveta Research in collaboration with a Harvard Medical School researcher explore use of obesity treatments in youth before and after new comprehensive guidelines for obesity management were published by the American Academy of Pediatrics (AAP). In a study of 329,357...
by Truveta Research | Jul 23, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2024 increased slightly relative to March 2024 (+8.43%). Month-over-month anti-diabetic medication (ADM) prescribing increased in April and May 2024 then decreased slightly in June...
by Truveta staff | Mar 29, 2024 | Research
Prior to the new Medicare guidelines going into effect, Truveta Research and Zeke Emanuel, MD, PhD from the University of Pennsylvania, explored the first-time prescribing and dispensing of anti-obesity GLP-1 RA medications for US adults aged 60 to 69 with obesity or...
